You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

TRAVOPROST Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Travoprost, and when can generic versions of Travoprost launch?

Travoprost is a drug marketed by Alembic, Apotex, Chartwell Rx, Micro Labs, and Mylan. and is included in five NDAs.

The generic ingredient in TRAVOPROST is travoprost. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Travoprost

A generic version of TRAVOPROST was approved as travoprost by CHARTWELL RX on March 1st, 2013.

  Try a Trial

Drug patent expirations by year for TRAVOPROST
Drug Prices for TRAVOPROST

See drug prices for TRAVOPROST

Drug Sales Revenue Trends for TRAVOPROST

See drug sales revenues for TRAVOPROST

Recent Clinical Trials for TRAVOPROST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Salus UniversityPhase 4
Assiut UniversityPhase 4
Glaukos CorporationPhase 3

See all TRAVOPROST clinical trials

Pharmacology for TRAVOPROST
Medical Subject Heading (MeSH) Categories for TRAVOPROST
Anatomical Therapeutic Chemical (ATC) Classes for TRAVOPROST
Paragraph IV (Patent) Challenges for TRAVOPROST
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IZBA Ophthalmic Solution travoprost 0.003% 204822 1 2015-12-30
TRAVATAN Z Ophthalmic Solution travoprost 0.004% 021994 1 2009-02-19
TRAVATAN Ophthalmic Solution travoprost 0.004% 021257 1 2008-11-28

US Patents and Regulatory Information for TRAVOPROST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 210458-001 Dec 20, 2019 AT1 RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Micro Labs TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 203767-001 Mar 19, 2021 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Apotex TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 203431-001 Jul 10, 2015 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 091340-001 Mar 1, 2013 AT1 RX No Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Mylan TRAVOPROST travoprost SOLUTION/DROPS;OPHTHALMIC 205050-001 Jul 7, 2017 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for TRAVOPROST

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Izba travoprost EMEA/H/C/002738
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Authorised no no no 2014-02-20
Novartis Europharm Limited Travatan travoprost EMEA/H/C/000390
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
Authorised no no no 2001-11-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.